BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 3149047)

  • 21. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha.
    Orbe J; Chordá C; Montes R; Páramo JA
    Haematologica; 1999 Apr; 84(4):306-11. PubMed ID: 10190943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An enzyme-linked immunosorbent assay (ELISA) used to study the cellular secretion of endothelial plasminogen activator inhibitor (PAI-1).
    MacGregor IR; Booth NA
    Thromb Haemost; 1988 Feb; 59(1):68-72. PubMed ID: 3129808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2.
    Alessi MC; Juhan-Vague I; Kooistra T; Declerck PJ; Collen D
    Thromb Haemost; 1988 Dec; 60(3):491-4. PubMed ID: 3149048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells.
    Marsh NA; Minter AJ; Chesterman CN
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):133-8. PubMed ID: 1966669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombin induces endothelial cell-surface exposure of the plasminogen receptor annexin 2.
    Peterson EA; Sutherland MR; Nesheim ME; Pryzdial EL
    J Cell Sci; 2003 Jun; 116(Pt 12):2399-408. PubMed ID: 12724354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of anti-endothelial/antiphospholipid antibodies on fibrin formation and lysis on endothelial cells.
    Patterson AM; Ford I; Graham A; Booth NA; Greaves M
    Br J Haematol; 2006 May; 133(3):323-30. PubMed ID: 16643435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelial cells organize fibrin clots into structures that are more resistant to lysis.
    Jerome WG; Handt S; Hantgan RR
    Microsc Microanal; 2005 Jun; 11(3):268-77. PubMed ID: 16060980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A plasma clot lysis assay based on the release of fibrin degradation products: application to the diagnosis of hypofibrinolytic states.
    Gaussem P; Gandrille S; Molho-Sabatier P; Capron L; Fiessinger JN; Aiach M
    Thromb Haemost; 1990 Feb; 63(1):76-81. PubMed ID: 2111050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha.
    Muth H; Maus U; Wygrecka M; Lohmeyer J; Grimminger F; Seeger W; Günther A
    Crit Care Med; 2004 Jan; 32(1):217-26. PubMed ID: 14707582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
    J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
    Nakamura R; Umemura K; Hashimmoto H; Urano T
    Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Herpesviruses enhance fibrin clot lysis.
    Gershom ES; Vanden Hoek AL; Meixner SC; Sutherland MR; Pryzdial EL
    Thromb Haemost; 2012 Apr; 107(4):760-8. PubMed ID: 22318336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
    Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
    Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor.
    Sakata Y; Loskutoff DJ; Gladson CL; Hekman CM; Griffin JH
    Blood; 1986 Dec; 68(6):1218-23. PubMed ID: 3096399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour.
    Dong Q; Zhou MH; Subbarao V; Ts'ao CH
    Br J Exp Pathol; 1988 Oct; 69(5):685-95. PubMed ID: 3143395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells.
    Schleef RR; Wagner NV; Loskutoff DJ
    J Cell Physiol; 1988 Feb; 134(2):269-74. PubMed ID: 3257967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Astrocyte regulation of human brain capillary endothelial fibrinolysis.
    Kim JA; Tran ND; Wang SJ; Fisher MJ
    Thromb Res; 2003; 112(3):159-65. PubMed ID: 14967413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression.
    Konkle BA; Ginsburg D
    J Clin Invest; 1988 Aug; 82(2):579-85. PubMed ID: 3136192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.